Why the study?
The optimal duration of dual antiplatelet therapy after PCI in patients at high bleeding risk is still debated.
Does abbreviated DAPT (1-3 months) reduce bleeding without increasing ischemic events compared to standard DAPT (≥6 months) in high bleeding risk patients undergoing PCI?
Does abbreviated DAPT (1-3 months) reduce bleeding without increasing ischemic events compared to standard DAPT (≥6 months) in high bleeding risk patients undergoing PCI?
In high bleeding risk patients undergoing PCI, an abbreviated 1- to 3-month DAPT strategy significantly reduces bleeding risk without increasing the risk of major adverse cardiovascular events compared to standard ≥6-month DAPT.
Answers are grounded in this paper and cite their sources.
Captured external expert commentary on this paper, strongest first. Original sources are linked where available.
“A one-month or 3-month DAPT courses after PCI appears an appealing treatment option in HBR patients to optimize outcomes. Further studies are warranted to determine how to individualize the decision between 1- and 3-month DAPT and the role of single antiplatelet therapy after DAPT.”
“One month of DAPT after PCI in high bleeding risk patients maintained the ischemic benefits of therapy while reducing the risk of bleeding. Unlike other studies, we did not exclude patients with acute coronary syndrome or limit the number, location, or complexity of the treated lesions. Our results can therefore inform treatment decisions on DAPT at one month after PCI in patients at high risk for bleeding without postprocedural ischemic events, including those with clinical or angiographic high ischemic risk features.”
“The findings of Valgimigli and colleagues are important and move us toward a shorter and simpler antithrombotic strategy after PCI. Concomitant shorter antiplatelet monotherapy in the context of chronic disease after the implantation of a drug-eluting stent represents a major shift. This news is welcome for patients at high risk for bleeding after stent placement.”
Clinicians should consider abbreviated DAPT to lower bleeding; reinforces ischemic safety and extends evidence for personalized therapy.
Aims The optimal duration of dual antiplatelet therapy (DAPT) after percutaneous coronary intervention (PCI) in patients at high bleeding risk (HBR) is still debated. We appraised an abbreviated compared with a more prolonged DAPT regimen in this setting by using the totality of existing evidence. Methods and results A systematic review and meta-analysis was performed to search randomized clinical trials comparing abbreviated (i.e., short [3 months] or very-short [1 month]) with standard (≥6 months) DAPT in HBR patients. Six trials with 8,409 patients were included. Major or clinically relevant non-major bleeding (MCRB) and major adverse cardiovascular events (MACE) were the co-primary safety and efficacy endpoints. MCRB was lower with abbreviated compared to standard DAPT (risk ratio [RR] 0.63, 95% CI 0.41–0.95; I2=74%). No difference in terms of MACE (RR 1.03, 95% CI 0.89–1.20; I2=0%) all-cause death, cardiovascular death, stent thrombosis or myocardial infarction were observed. Network meta-analysis showed short or very-short DAPT to have the highest probability to prevent bleeding in HBR patients. Conclusion Abbreviated DAPT reduced bleeding without apparent increase in ischemic events in HBR patients undergoing PCI. Three-month or one-month DAPT courses appeared similarly effective to optimize the trade-off for ischemia and bleeding in this population.
No takes yet. Share an insight, caveat, or question.
Costa et al. (2022) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: